Dendreon Corp. expects first-quarter sales to be slower than in the fourth quarter, when sales of its prostate cancer treatment Provenge were $77 million. The Seattle drug maker said first-quarter revenue growth for the drug would be in the low single digits. Fourth-quarter net income was $38.1 million, or 26 cents a share. Profit excluding some items was 45 cents a share. Analysts expected 60 cents.